- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5 result(s) found for: Prostatic acid phosphatase.
Displaying page 1 of 1.
EudraCT Number: 2005-004378-25 | Sponsor Protocol Number: PC SOR-101 | Start Date*: 2005-12-14 | |||||||||||
Sponsor Name:Urologische Klinik und Poliklinik, Klinikum Großhadern der LMU München | |||||||||||||
Full Title: A randomized, double-blinded, multicentric phase II trial to optimize the treatment of the hormon refractory prostatic carcinoma in patients without preceding chemotherapy with Sorafenib + Docetaxe... | |||||||||||||
Medical condition: Locally progressed and / or metastasized hormon refractory prostate carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008692-33 | Sponsor Protocol Number: 2008-242 | Start Date*: 2009-04-21 | ||||||||||||||||
Sponsor Name:Department of Urology, Herlev Hospital | ||||||||||||||||||
Full Title: Evaluation of cytotoxicity and genetic changes of high dose vitamin C infusions in castration resistant metastatic human prostate cancer. | ||||||||||||||||||
Medical condition: The effect of high dose intravenous weekly vitamin c infusion in castration resistant human prostate cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005999-13 | Sponsor Protocol Number: D8180C00034 | Start Date*: 2008-02-21 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase II, Randomised, Open-label, Pilot Study to Evaluate the Safety and the Effects on Bone Resorption of AZD0530 in Patients with Prostate Cancer or Breast Cancer with Metastatic Bone Disease ... | ||
Medical condition: Prostate Cancer or Breast Cancer with Metastatic Bone Disease Cáncer de próstata o de mama con metástasis óseas | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) GB (Completed) SE (Completed) PT (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001128-31 | Sponsor Protocol Number: 13-23 | Start Date*: 2014-09-23 | |||||||||||
Sponsor Name:Cancer Trials Ireland | |||||||||||||
Full Title: Phase II Single-arm Study evaluating Neo-adjuvant (pre-radical radiotherapy) Abiraterone acetate (plus prednisolone) and Gonadotropin-Releasing Hormone (GnRH) agonist in high risk localised prostat... | |||||||||||||
Medical condition: High-risk prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001236-28 | Sponsor Protocol Number: R39_21_01 | Start Date*: 2023-01-13 | |||||||||||
Sponsor Name:Fidia Farmaceutici S.p.A. | |||||||||||||
Full Title: A phase III, single-arm study to evaluate the efficacy and safety of ONCOFID-P-B (paclitaxel-hyaluronic acid conjugate) administered intravesically to patients with BCG-unresponsive Carcinoma in Si... | |||||||||||||
Medical condition: BCG-unresponsive Carcinoma in Situ of the bladder with or without Ta-T1 papillary disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
